OBJECTIVES: SSc is a CTD characterized by vascular involvement, with generalized disturbance of the microcirculation, which may lead to pulmonary artery hypertension (PAH). Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor. Increased concentrations of plasma ADMA may also contribute to endothelial dysfunction in patients with pulmonary vascular disease. The aim of our study was to elucidate the possible relationship between serum ADMA and PAH in patients with SSc. Moreover, we sought to investigate the effect of ADMA levels on the functional capacity of these patients. METHODS: Plasma ADMA levels were measured in 66 patients with SSc (63 females, mean age 57.8 +/- 12.8 yrs, median duration of disease 9.9 yrs, 47 with lcSSc and 19 with dcSSc disease) and 30 healthy controls (29 females, mean age 58.2 +/- 8.4 yrs). Systolic pulmonary artery pressure (sPAP) assessed by echocardiography, lung function tests, 6-min walk test (6MWT) and serum ADMA levels were recorded from patients. RESULTS: In 24 patients, the diagnosis of PAH was established. Mean value of ADMA for SScPAH patients was 0.44 +/- 0.22 micromol/l compared with 0.26 +/- 0.18 micromol/l for patients without PAH and 0.25 +/- 0.20 micromol/l for controls (P = 0.001). ADMA levels were inversely correlated with the 6MWT (r = -0.55, P = 0.005). CONCLUSIONS: In patients with SScPAH, increased ADMA serum levels and their negative association with exercise capacity suggests that the NO pathway is involved in the development of pulmonary vascular disease.
OBJECTIVES: SSc is a CTD characterized by vascular involvement, with generalized disturbance of the microcirculation, which may lead to pulmonary artery hypertension (PAH). Asymmetrical dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor. Increased concentrations of plasma ADMA may also contribute to endothelial dysfunction in patients with pulmonary vascular disease. The aim of our study was to elucidate the possible relationship between serum ADMA and PAH in patients with SSc. Moreover, we sought to investigate the effect of ADMA levels on the functional capacity of these patients. METHODS: Plasma ADMA levels were measured in 66 patients with SSc (63 females, mean age 57.8 +/- 12.8 yrs, median duration of disease 9.9 yrs, 47 with lcSSc and 19 with dcSSc disease) and 30 healthy controls (29 females, mean age 58.2 +/- 8.4 yrs). Systolic pulmonary artery pressure (sPAP) assessed by echocardiography, lung function tests, 6-min walk test (6MWT) and serum ADMA levels were recorded from patients. RESULTS: In 24 patients, the diagnosis of PAH was established. Mean value of ADMA for SScPAH patients was 0.44 +/- 0.22 micromol/l compared with 0.26 +/- 0.18 micromol/l for patients without PAH and 0.25 +/- 0.20 micromol/l for controls (P = 0.001). ADMA levels were inversely correlated with the 6MWT (r = -0.55, P = 0.005). CONCLUSIONS: In patients with SScPAH, increased ADMA serum levels and their negative association with exercise capacity suggests that the NO pathway is involved in the development of pulmonary vascular disease.
Authors: Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin Journal: Eur J Pediatr Date: 2010-12-01 Impact factor: 3.183
Authors: Stephanos Pavlides; Aristotelis Tsirigos; Gemma Migneco; Diana Whitaker-Menezes; Barbara Chiavarina; Neal Flomenberg; Philippe G Frank; Mathew C Casimiro; Chenguang Wang; Richard G Pestell; Ubaldo E Martinez-Outschoorn; Anthony Howell; Federica Sotgia; Michael P Lisanti Journal: Cell Cycle Date: 2010-09-01 Impact factor: 4.534
Authors: Daniel L Edmonston; Kishan S Parikh; Sudarshan Rajagopal; Linda K Shaw; Dennis Abraham; Alexander Grabner; Matthew A Sparks; Myles Wolf Journal: Am J Kidney Dis Date: 2019-11-12 Impact factor: 8.860
Authors: Rushi V Parikh; Rebecca Scherzer; Elaine M Nitta; Anna Leone; Sophia Hur; Vanita Mistry; John S Macgregor; Jeffrey N Martin; Steven G Deeks; Peter Ganz; Priscilla Y Hsue Journal: AIDS Date: 2014-02-20 Impact factor: 4.177
Authors: Anna Sandqvist; Dan Henrohn; Hanna Egeröd; Mikael Hedeland; Lisa Wernroth; Ulf Bondesson; Jörn Schneede; Gerhard Wikström Journal: Eur J Clin Pharmacol Date: 2015-08-05 Impact factor: 2.953
Authors: Dariusz Zakrzewicz; Anna Zakrzewicz; Klaus T Preissner; Philipp Markart; Malgorzata Wygrecka Journal: Int J Mol Sci Date: 2012-09-27 Impact factor: 5.923